APA (7th ed.) Citation

Antonia, S. J., & Jäger, D. (2016). Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC). Annals of oncology, 27, . https://doi.org/10.1093/annonc/mdw383.16

Chicago Style (17th ed.) Citation

Antonia, Scott J., and Dirk Jäger. "Phase 1/2 Study of the Safety and Clinical Activity of Durvalumab in Patients with Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology 27 (2016). https://doi.org/10.1093/annonc/mdw383.16.

MLA (9th ed.) Citation

Antonia, Scott J., and Dirk Jäger. "Phase 1/2 Study of the Safety and Clinical Activity of Durvalumab in Patients with Non-small Cell Lung Cancer (NSCLC)." Annals of Oncology, vol. 27, 2016, https://doi.org/10.1093/annonc/mdw383.16.